Interestingly, in our series 3/4 EGFR mutant patients with progressive disease after EGFR TKI treatment had coexisting mutations in KRAS or BRAF in the primary tumor, in two cases at an allelic frequency higher than EGFR mutations. Here, EGFR is linked to neoplasm.